We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+9.23%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.19B
AUM Growth
+$35.3M
Cap. Flow
+$22.8M
Cap. Flow %
0.54%
Top 10 Hldgs %
34.58%
Holding
124
New
4
Increased
47
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$19.7M
2
RVMD icon
Revolution Medicines
RVMD
+$17.3M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$15.3M
4
PLRX icon
Pliant Therapeutics
PLRX
+$14M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.7M

Top Sells

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$58.6M
2
PEN icon
Penumbra
PEN
+$19.1M
3
IMCR icon
Immunocore
IMCR
+$18M
4
ALGN icon
Align Technology
ALGN
+$16.2M
5
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.08%
2 Consumer Staples 1.05%
3 Industrials 0.87%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ETNB
101
CALL
DELISTED
89bio
ETNB
$2.51M 0.06%
+164,500
New +$2.14M
FULC icon
102
Fulcrum Therapeutics
FULC
$279M
$2.07M 0.05%
727,673
+343,083
+89% +$3.07M
TPST icon
103
Tempest Therapeutics
TPST
$18.9M
$1.91M 0.05%
63,358
– –
GMDA
104
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$1.9M 0.05%
2,344,649
-1,775,234
-43% -$2.59M
CYPH
105
Cypherpunk Technologies Inc
CYPH
$71.6M
$1.58M 0.04%
465,519
+99,534
+27% +$522K
EPIX
106
DELISTED
ESSA Pharma
EPIX
$1.56M 0.04%
524,944
– –
NKTX icon
107
Nkarta
NKTX
$167M
$1.4M 0.03%
393,389
– –
GOSS icon
108
Gossamer Bio
GOSS
$85.2M
$1.39M 0.03%
1,100,274
+724,226
+193% +$1.39M
SYRE icon
109
Spyre Therapeutics
SYRE
$8.89B
$990K 0.02%
136,556
– –
SPRO icon
110
Spero Therapeutics
SPRO
$70.1M
$971K 0.02%
669,533
– –
ALT icon
111
Altimmune
ALT
$593M
$942K 0.02%
223,255
– –
VINC
112
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$927K 0.02%
44,586
– –
CGEN icon
113
Compugen
CGEN
$226M
$906K 0.02%
1,289,990
– –
APLT
114
DELISTED
Applied Therapeutics
APLT
$633K 0.02%
780,791
+184,111
+31% +$181K
BCEL
115
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$413K 0.01%
362,530
– –
TLPH icon
116
Talphera
TLPH
$73.2M
$208K 0.01%
316,460
– –
NUVB.WS
117
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$16.1K ﹤0.01%
134,028
– –
BAX icon
118
Baxter International
BAX
$14.3B
– –
-1,150,000
Closed -$58.6M
FSTX
119
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
– –
-751,889
Closed -$4.75M
CINC
120
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
– –
-1,116,578
Closed -$13.7M
1 2 3 4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Rock Springs Capital Management held 124 positions worth $4.19B, up 0.85% from $4.16B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rock Springs Capital Management's Q1 2023 filing shows 4 new, 47 increased, 8 reduced and 3 closed positions. Its largest new stake was Mineralys Therapeutics: 1,167,492 shares worth $18.3M. The largest sale was Baxter International, an estimated $58.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q1 2023 buy was Mineralys Therapeutics: 1,167,492 shares worth $18.3M.
  • Rock Springs Capital Management added most to Karuna Therapeutics, Inc. Common Stock in Q1 2023, an estimated $15.3M increase.
  • Rock Springs Capital Management's biggest Q1 2023 reduction was Penumbra, cutting an estimated $19.1M.
  • Rock Springs Capital Management fully exited Baxter International in Q1 2023, selling an estimated $58.6M.
  • Rock Springs Capital Management's ten largest holdings make up 35% of its $4.19B portfolio in Q1 2023.
  • Rock Springs Capital Management opened 4 new positions and closed 3 in Q1 2023.
  • Rock Springs Capital Management's portfolio value rose 0.85% quarter-over-quarter to $4.19B.

Based on Rock Springs Capital Management's 13F filing for Q1 2023, filed 15 May 2023.